Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657316 | 1.00 | HDAC1 (0.56) | HDAC1HDAC6HDAC8EGFRERBB2 | |
| SCHEMBL15480654 | 0.84 | HDAC6 (0.72) | HDAC1HDAC6HDAC8ALDH1A1HPGD | |
| SCHEMBL5943921 | 0.83 | HDAC6 (0.71) | HDAC1HDAC6HDAC8SMN1; SMN2 | |
| SCHEMBL15480652 | 0.83 | HDAC6 (0.56) | HDAC1HDAC6HDAC8EGFRERBB2 | |
| SCHEMBL4659080 | 0.83 | HDAC6 (0.67) | HDAC1HDAC6HDAC8ALDH1A1SMN1; SMN2 | |
| SCHEMBL4610487 | 0.83 | HDAC1 (0.61) | HDAC1HDAC6HDAC8EGFRERBB2 | |
| SCHEMBL4659287 | 0.83 | HDAC6 (0.67) | HDAC1HDAC6HDAC8ALDH1A1SMN1; SMN2 | |
| SCHEMBL21652258 | 0.83 | SMN1; SMN2 (0.48) | EGFRERBB2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4657405 | 0.80 | HDAC1 (0.69) | HDAC1HDAC6HDAC8 | |
| SCHEMBL4654851 | 0.80 | HDAC1 (0.69) | HDAC1HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | claimed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | claimed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | claimed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | claimed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | claimed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | claimed |
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | disclosed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | disclosed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | disclosed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | disclosed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | HDAC7, SIRT7, HCAR1 | HDAC1 67/4885HDAC6 201/4885HDAC8 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.